Zhongxin Finance, April 16. According to the "China Bio" WeChat public account on the 16th, recently, two new coronavirus inactivated vaccines (Austria) were developed by Sinopharm China Bio-Beijing Biological Products Research Institute and Wuhan Biological Products Research Institute. The Mikron variant, hereinafter referred to as "O strain") has been approved by the University of Hong Kong and the Hong Kong Island Western Hospital Network Research Ethics Committee of the Hospital Authority, as well as the approval of the clinical trial from the Hong Kong Pharmacy and Poisons Authority, and has been officially approved to carry out in Hong Kong Sequential immunization clinical study of new crown vaccine.
According to reports, both vaccines were inoculated into Vero cells with Omicron strains, and were made by culturing, inactivating, purifying, and adsorbing with aluminum hydroxide adjuvant.
In the next step, Sino Bio will use a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the BIBP-novel coronavirus inactivated vaccine The safety and immunogenicity of two vaccines (O strain) and WIBP-novel coronavirus inactivated vaccine (O strain).
(Finish)